SentreHEART is a private medical device company that develops catheter and MIS surgical technology for suture delivery and tissue closure. The company’s LARIAT device is used to exclude the left atrial appendage in persistent or long standing persistent AFib patients.
This treatment plays a critical role in the restoration and maintenance of normal sinus rhythm and can protect against thromboembolism. Deerfield led SentreHEART’s $35 million Series D financing. The funding will be used to conduct the aMAZE trial, a randomized pivotal FDA study of the LARIAT device to demonstrate safety and efficacy in reducing the burden of AFib.